{"name":"BioDlink Biopharm Co., Ltd.","slug":"biodlink-biopharm-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"TAB008","genericName":"TAB008","slug":"tab008","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"TAB014 Monoclonal Antibody Injection","genericName":"TAB014 Monoclonal Antibody Injection","slug":"tab014-monoclonal-antibody-injection","indication":"Unspecified indication","status":"phase_3"}]}],"pipeline":[{"name":"TAB008","genericName":"TAB008","slug":"tab008","phase":"phase_3","mechanism":"TAB008 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"TAB014 Monoclonal Antibody Injection","genericName":"TAB014 Monoclonal Antibody Injection","slug":"tab014-monoclonal-antibody-injection","phase":"phase_3","mechanism":"TAB014 is a monoclonal antibody that targets an unspecified molecular target to treat various conditions.","indications":["Unspecified indication"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxQaFNoS1ZjbjFKdS12bnBYN1dGRUpqbTNVVkdINkRVLVRCWUl5Nno1aDdIV2hncTdLYkZNZG1HZHRtWDZKRzlId041RGRyMDlNVWpmcDVELUp6RkxnRzh0U2dHVnhXcXN5b1RSSXNaRzFKRGNSN2JqNU13VjUtZEZhRGF3TFFoYVZIME5pdEJMaFBKUFpoTVdYcWpUcC1CbGJwX2ZlRjBGU0JHbHBOOTR1RXNjSFFvRFA0bWtTbTdmUjJXazhBNTNCaWUxUVlZdm5CenM1SHcwX2dIQ0hWdDYzNlF4MA?oc=5","date":"2026-03-13","type":"pipeline","source":"PR Newswire","summary":"BioDlink Named \"Emerging CDMO of the Year\" at the 2026 Asia-Pacific Biopharma Excellence Awards - PR Newswire","headline":"BioDlink Named \"Emerging CDMO of the Year\" at the 2026 Asia-Pacific Biopharma Excellence Awards","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxOQ0NMWFFJZ2Vab0lQMFFvTjE5TTd3TnJ5UkN1STRIZE5iV1F4QzdUU0pNV2paeEpHay1OdnduWE9yQ2RUZXBwYnVEZDZqWnZOTmRURWNiYmtYRVctdG83b0ZLaVhJMWNINXRsMGM2S1V4dlFNTDJ5b0taNjVLS2s1Q0RPc2RLOGlpbDYxOUNlQUpMTjlXeTJXZmctLVBJZm5VdkdDb3Y0U1FIMmZ5QTRWSGE3VUhWTnA4VVQzSkdhTENZVGdJSnRGc2VLTVV3VUtKVWc?oc=5","date":"2025-11-28","type":"deal","source":"PR Newswire","summary":"BioDlink Showcases Europe-China CMC Collaboration Amid Developmental Breakthrough - PR Newswire","headline":"BioDlink Showcases Europe-China CMC Collaboration Amid Developmental Breakthrough","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxPRVdvcjFvdmVSOWJGckZzNkk0NnZNTXNZd1padTBSZ2NCQkRrMHJSZ0pCbUlWOEc5WkJUQmpkZGVGWU5kblYyM182a1Rvc3JxQ0M5UUFVTVN1RUk5T2hTemVhVU9VSFdKQm9SNXVHSVIxVlpkVm0yWnlybkxrWWxFclJtZTdCRVRjWWJvLVlzMFV0VDZ4QzFYbUJtRm1wVEJKeUROTElwS01oTEtMYVVFcVBOUTZEck8wTVdCVHhuUVNpcnZoTXRrZ0pxOXNoVEh3bHk1QjJsWGRESDlUSGNmZ1VOMmRIOUJQUVRDTDVUTDk2VTB6bUNUYVhGN0U1aWxJeFo5NjZOaWRHYUMwU2lOUzlTNmlwejFseFBkWG9QZC1NLUFmYzFxMlB2d2pKS2NmSkNCR0FmM040T2lHRHN6UHpUWTg?oc=5","date":"2025-11-21","type":"deal","source":"PR Newswire","summary":"BioDlink and Lepu Biopharma Celebrate Successful Launch of the World's First EGFR-Targeting ADC Drug, Marking a Major Milestone in Mutual Collaboration in Biologics CMC - PR Newswire","headline":"BioDlink and Lepu Biopharma Celebrate Successful Launch of the World's First EGFR-Targeting ADC Drug, Marking a Major Mi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxNLXM5aUw4LWcxcUZJZ2RzOFRSZUtyNkEzQjNrUmY5cWRiMFJWT29JRldEZzA1Z1d1b1N2UFVWYzE1NldZbmJ1OWRmRG9KRjhlSkg4d0xnZlRXeERsUE5mUWFtMnE4YjJydGJQWXdyLXJNTlBsMlVFbV91UERNUm45T0cwUENMTEV0OFU1MmhIZjJ5VVpZSUFxcDI0dnp1SnU4Q1AwZVZXU1NldGlOOWpFUFNpd2dUSi1yNGlpMWtRNWM4NWktMWhVclVYc0JLNWxzYzNCcW1KbGhsQkVLN2JsZUFiZzRTNk8xWG1oUWZBeEpjb0tW?oc=5","date":"2025-11-05","type":"regulatory","source":"PR Newswire","summary":"BioDlink Congratulates Lepu Biopharma on Securing Approval for the World's First Approved EGFR-Targeted ADC - PR Newswire","headline":"BioDlink Congratulates Lepu Biopharma on Securing Approval for the World's First Approved EGFR-Targeted ADC","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxNNWhUNjZGN2FoUUVzTTR4TWZwTXY1TEF2dXVaMy1WaFQ2UEVXaWNUd1NoNHM5aTNUZVJpclJRT0xsaHNyaWYwX0YzaTlhM2JMQ1d2M0RIZExLRkkyTDJmbUZ6SXp5UVpzeGpuYlp4RHczQ05scDV4YWRWN19rSGdfZEc1cWp6ZXhwMEI4Mm9FUElQZUV2UmFiNEJ6dmtZTWtxempjY1c4LVhiUVVIdVNIVENOVW8yLUoxd0dKVjFIOGlYRlRWcGxZdEln?oc=5","date":"2025-10-27","type":"pipeline","source":"PR Newswire","summary":"BioDlink Completes First International Shipment of Bevacizumab to Colombia - PR Newswire","headline":"BioDlink Completes First International Shipment of Bevacizumab to Colombia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPOXVvTVhGeFdZLXRGQ1dqOFFjeTdYLUtBSWZGdlRaRllwS0ZJMVF0c205c3FBaWZCWjNtRUFHaXBIZDBiQm12QzcyeC0yTjNxcFVmYWpnUThrSUNjeHNZQ3l0THpyWk5OcEtBUUNkeUoyOW1mOTdYZVc2eXl4dlNGNXRWckFhRHhTZHhxOE1obGVJNHR1OXJrUnkzNEYybEFvOTZpNDFGU3FtVWtnVDhTR2I2Yy1uM3htaVFaX1NId2h2SV9nRXY1Ny0xNl9pdEk4V1RlUnU2WVM4dw?oc=5","date":"2025-08-13","type":"pipeline","source":"PR Newswire","summary":"BioDlink Accelerates Global Expansion with Bevacizumab Launch in Colombia and Pakistan - PR Newswire","headline":"BioDlink Accelerates Global Expansion with Bevacizumab Launch in Colombia and Pakistan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQeGt6YW5oT2h3dGFGYnkxZ0NXUHFJZ2dkZUE2OFY5X1VSVVBFbUpPSGpuVWhETkpmaEg4UVhIVlY1eWdoWHAzSVJQejNnWmZiOFM4M0pKbTJJVUszeFZNbm1RWkRpY05sQk5wcVpwUGJ2UExzY0cxUHVzNXZVaUI3X3BVeFNwX2xEOEp4QTBjMVI4WGF1QzVKZE5FbG1hNjlBeTZ3bmRaaFlDWUpJcnplekpkY1QtY2FJdmdSM0FIWjI?oc=5","date":"2025-07-04","type":"deal","source":"PR Newswire","summary":"BioDlink Drives Global Biologics Innovation with Ecosystem Partners - PR Newswire","headline":"BioDlink Drives Global Biologics Innovation with Ecosystem Partners","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQZ3lqWUtxTmhjMUdHUU1Rb3h2WVpyWmxSRFZTT3pLZVZ4Yndaa3U0TktsSUxoa3VhTWtEcEtqNFZKYjBCcmhaRW14TEc4ZjlVRng5THhjQnRBM0hXM2h4dzIzRjljelBnYVdzajRubnh0U1g5YVQyM3NlYmpLSE5Ecm1tWUljR3Y5SGltR0llRDdFWmRBbHFJN1JQWVg2MmhSVzJxbTMzby1uR0xlRldIanlnYmhKTlBZOVdnRWlLNFdkMEJaenc?oc=5","date":"2025-06-05","type":"pipeline","source":"PR Newswire","summary":"BioDlink Strengthens Global Compliance with Argentina GMP Certification - PR Newswire","headline":"BioDlink Strengthens Global Compliance with Argentina GMP Certification","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPTnYwaHFpNEtXVk1TWlA5c0JZZ01VMmstYnFOdC1JYmJnUTg5TnpYRUpLTktrYllXUnA2ck8wYm5XZy01RUVfYjJRTklnV3VKMDBUWmV6MmhUMUFsZnh2T1B5Z3lqRUlwWVlIODhrSmQyUk5TWkVETGlzc0tIVlgwXzNYUmYzbkM1OUtZZndxQjBlWllWS0QtY3I5VC05X2RETWVXTHN5MVBRLUhKdVZGMjBIQUt2UGdFWGxLYm9UdFAxM29NVHRJ?oc=5","date":"2025-05-21","type":"pipeline","source":"PR Newswire","summary":"BioDlink Clinches Brazil GMP Audit to Strengthen Emerging Markets Growth - PR Newswire","headline":"BioDlink Clinches Brazil GMP Audit to Strengthen Emerging Markets Growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxPTElRQWR4eGJ0MHJ5VVZDU0tiUGxSZ0c3aWJBWHFZNVJIWDRZU3BpY3Fzb01zb3dKWC1tVWdWazJlTWxHT05zM0hMNmpuOXhETkZVVGpicFFFczBvcm9DMzV0Mm9LZ1ItaGl4OXAzakk2dFBLX1pJc1V4eGUtM3U5Y3doU01DQ3FQX2pVUXM2bEh1ME1waENwYW81TVdLeUloR2pTdW5rNDFiYTBfT05vb0RZQjBJaHo4Wnd5VVZyZV9XQW5icW9iU2c5VlZMZ29zTHBqU3UxaWhIOHFtSEgxTWg2bkFCRVd3ellyRUQ0M1ZGdTQ?oc=5","date":"2025-05-08","type":"regulatory","source":"PR Newswire","summary":"BioDlink Congratulates Junshi Biosciences on IND Approval of JS212, a Bispecific ADC Therapeutic Candidate - PR Newswire","headline":"BioDlink Congratulates Junshi Biosciences on IND Approval of JS212, a Bispecific ADC Therapeutic Candidate","sentiment":"positive"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}